JP2016540045A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540045A5
JP2016540045A5 JP2016554526A JP2016554526A JP2016540045A5 JP 2016540045 A5 JP2016540045 A5 JP 2016540045A5 JP 2016554526 A JP2016554526 A JP 2016554526A JP 2016554526 A JP2016554526 A JP 2016554526A JP 2016540045 A5 JP2016540045 A5 JP 2016540045A5
Authority
JP
Japan
Prior art keywords
benzoic acid
ethynyl
phenylethynyl
pyrrol
indol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016554526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540045A (ja
JP6744218B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/065765 external-priority patent/WO2015073864A1/en
Publication of JP2016540045A publication Critical patent/JP2016540045A/ja
Publication of JP2016540045A5 publication Critical patent/JP2016540045A5/ja
Application granted granted Critical
Publication of JP6744218B2 publication Critical patent/JP6744218B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016554526A 2013-11-15 2014-11-14 Ebna1阻害剤およびそれらの使用方法 Active JP6744218B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904555P 2013-11-15 2013-11-15
US61/904,555 2013-11-15
PCT/US2014/065765 WO2015073864A1 (en) 2013-11-15 2014-11-14 Ebna1 inhibitors and their method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020129107A Division JP2020196723A (ja) 2013-11-15 2020-07-30 Ebna1阻害剤およびそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2016540045A JP2016540045A (ja) 2016-12-22
JP2016540045A5 true JP2016540045A5 (https=) 2017-11-30
JP6744218B2 JP6744218B2 (ja) 2020-08-19

Family

ID=53058091

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016554526A Active JP6744218B2 (ja) 2013-11-15 2014-11-14 Ebna1阻害剤およびそれらの使用方法
JP2020129107A Withdrawn JP2020196723A (ja) 2013-11-15 2020-07-30 Ebna1阻害剤およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020129107A Withdrawn JP2020196723A (ja) 2013-11-15 2020-07-30 Ebna1阻害剤およびそれらの使用方法

Country Status (10)

Country Link
US (4) US9856214B2 (https=)
EP (1) EP3068758B1 (https=)
JP (2) JP6744218B2 (https=)
KR (1) KR20160110357A (https=)
CN (1) CN105934425B (https=)
AU (2) AU2014348422B2 (https=)
BR (1) BR112016011079A2 (https=)
CA (1) CA2930584A1 (https=)
MX (1) MX2016006325A (https=)
WO (1) WO2015073864A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930584A1 (en) 2013-11-15 2015-05-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and their method of use
AU2016262572B2 (en) * 2015-05-14 2020-04-30 The Wistar Institute Of Anatomy And Biology EBNA1 inhibitors and methods using same
WO2017100819A1 (en) * 2015-12-14 2017-06-22 The Australian National University Modular syntheses of discoipyrrole type alkaloids and analogues
US11046731B2 (en) * 2018-01-18 2021-06-29 Hong Kong Baptist University Zinc-binder based EBNA1-specific compounds
EP3787669A4 (en) * 2018-04-30 2022-03-30 The Trustees of Indiana University COMPOUNDS FOR MODULATION OF LEVELS OF DDAH AND ADMA AND METHODS OF USE THEM TO TREAT DISEASES
EP3793546B1 (en) * 2018-05-17 2025-11-19 The Wistar Institute Ebna1 inhibitor crystalline forms, and methods of preparing and using same
CN113754541B (zh) * 2020-06-02 2025-01-03 深圳湾实验室 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
CN116135850A (zh) * 2021-11-16 2023-05-19 深圳湾实验室 抗鼻咽癌的小分子抑制剂、化合物的制备方法及其应用
WO2024050408A1 (en) * 2022-08-30 2024-03-07 The Wistar Institute Of Anatomy And Biology Development of a novel ebna-1 degrader targeting through mdm2
CN117586230B (zh) * 2023-10-20 2024-09-24 南方医科大学深圳医院 降解ebna1的protac化合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
HU190007B (en) * 1982-05-06 1986-08-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing new aromatic prostacylin analogues
DE3936297A1 (de) * 1989-11-01 1991-05-02 Bayer Ag Verfahren zur herstellung von symmetrischen diarylacetylenen
DE4039448A1 (de) * 1990-12-11 1992-06-17 Rhein Chemie Rheinau Gmbh Polyurethan-katalysatoren
US5356919A (en) * 1991-05-30 1994-10-18 G. D. Searle & Co. Leukotriene B4 synthesis inhibitors
US6166028A (en) * 1998-12-09 2000-12-26 American Home Products Corporation Diaminopuridine-containing thiourea inhibitors of herpes viruses
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) * 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
DZ3347A1 (fr) 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
ATE481385T1 (de) 2000-05-31 2010-10-15 Santen Pharmaceutical Co Ltd (pyridinyl)alkyl-amide oder -harnstoffe als tnf- alpha bildung inhibitoren
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20040044041A1 (en) * 2002-08-06 2004-03-04 Kuduk Scott D. 2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives
US7361743B2 (en) 2004-02-11 2008-04-22 Pfizer Inc Lincomycin derivatives possessing antibacterial activity
CN1288117C (zh) 2004-04-02 2006-12-06 中国科学院上海有机化学研究所 端基炔烃和芳基卤化物的偶联反应
AU2005259835B2 (en) * 2004-07-02 2011-07-07 The Walter And Eliza Hall Institute Of Medical Research Alpha-helical mimetics
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
AU2005268893B2 (en) 2004-08-05 2011-10-13 F. Hoffmann-La Roche Ag Indole, indazole or indoline derivatives
US7687623B2 (en) * 2005-05-12 2010-03-30 Wyeth Llc Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists
CN102206216B (zh) * 2005-06-22 2014-11-12 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
WO2007002587A2 (en) 2005-06-24 2007-01-04 The Brigham And Women's Hospital, Inc. Inhibitors of epstein barr virus nuclear antigen 1
WO2007023242A1 (en) * 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
US8022217B2 (en) * 2006-07-31 2011-09-20 Cadila Healthcare Limited Compounds suitable as modulators of HDL
US7956216B2 (en) * 2006-12-21 2011-06-07 The Walter And Eliza Hall Institute Of Medical Research Alpha-helical mimetics
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
US8273769B2 (en) 2009-02-12 2012-09-25 Merck Serono Sa Phenoxy acetic acid derivatives
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
US20100273772A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5)
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2011082098A1 (en) 2009-12-30 2011-07-07 The Rockefeller University Lysine and arginine methyltransferase inhibitors for treating cancer
AU2011207679B2 (en) * 2010-01-19 2013-10-10 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
CN103502217B (zh) * 2011-01-21 2015-11-25 太阳医药高级研究有限公司 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼
WO2012162291A1 (en) * 2011-05-24 2012-11-29 The Wistar Institute Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1
US9725452B2 (en) * 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
CA2930584A1 (en) * 2013-11-15 2015-05-21 The Wistar Institute Of Anatomy And Biology Ebna1 inhibitors and their method of use

Similar Documents

Publication Publication Date Title
JP2016540045A5 (https=)
JP6203781B2 (ja) C−fmsおよび/またはc−kit活性を調節する化合物およびその用途
JP2012525431A5 (https=)
TWI617552B (zh) 用於激酶調節及其適應症之化合物及方法
AU2005216904B2 (en) Modulation of inflammatory and metastatic processes
JP5808793B2 (ja) キナーゼ調節のための化合物および方法、ならびにそれらの適応症
RU2386630C2 (ru) Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
JP4462930B2 (ja) ピリミジン化合物及びその医薬組成物
JP5815558B2 (ja) キナーゼ調節のための化合物及び方法ならびにそれらの適応症
WO2015134536A1 (en) Compounds and methods for kinase modulation, and indications therefor
RU2013123274A (ru) Аминопирролидиназетидиндиамиды как ингибиторы моноацилглицеринлипазы
CN104981247A (zh) 用于激酶调节的化合物和方法及其适应症
JP2006514110A5 (https=)
CA2451678A1 (en) Azaindoles
JP2012528178A5 (https=)
JP2016512825A5 (https=)
RU2010137114A (ru) Амидные производные как позитивные аллостерические модуляторы и способы их применения
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
TW200522952A (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
JP2014527529A5 (https=)
KR20100046189A (ko) 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
RU2012155712A (ru) Новые производные пиримидина
AU2019202905A1 (en) EBNA1 inhibitors and their method of use
ES2337596T3 (es) Antagonistas del receptor de glucacion, preparacion y usos terapeuticaos.
JP2018535930A (ja) 3−ヒドロキシ−キナゾリン−2,4−ジオン誘導体およびヌクレアーゼ調節因子としてのこの使用